Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328978
Status:
COMPLETED
Last Update Posted:
2009-03-25
First Post:
2006-05-22
Brief Title:
Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Canadian Multicenter Double-Blind Randomized Parallel-Group Study of the Safety Tolerability and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate Seroquel Greater Than 800 mgDay in Schizophrenic or Schizoaffective Subjects
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess and compare the side effect profile safety tolerability and efficacy of schizophrenic or schizoaffective subjects non- or partially- responsive to 800 mgday of quetiapine treated with either 800 mgday or more than 800 mgday of quetiapine during 8 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D1441C00023 | None | None | None |